{
    "nctId": "NCT06200168",
    "briefTitle": "Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer",
    "officialTitle": "A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)",
    "overallStatus": "RECRUITING",
    "conditions": "Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 370,
    "primaryOutcomeMeasure": "Proportion of patients with no nausea during the overall stage",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Aged 18 years or older and aged 75 years or younger, of any nationality;\n2. Eastern Cooperative Oncology Group performance status of 0-2;\n3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC\u22654)/cisplatin;\n4. Predicted life expectancy of \u22653 months;\n5. Adequate bone marrow, kidney, and liver function;\n6. Adequate contraception if premenopausal women;\n7. Written informed consent by the patient before enrolment.\n\nExclusion Criteria:\n\n1. Patients already submitted to chemotherapy;\n2. Is scheduled to receive any non-HEC on Day 1;\n3. Is scheduled to receive any chemotherapy on days 2-4 after HEC;\n4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;\n5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting;\n6. Have ongoing emesis or CTCAE grade 2 or greater nausea;\n7. Significant medical or mental conditions;\n8. Any allergies to study drug, antiemetics or dexamethasone;\n9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine);\n10. Patients who are pregnant or breast-feeding;\n11. Inflammatory skin reaction;\n12. Has lymphedema in acupuncture stimulation area;\n13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles;\n14. Received acupuncture treatments for any conditions less than 4 weeks before HEC;\n15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation));\n16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis;\n17. Has a convulsive disorder requiring anticonvulsant treatment;\n18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment);\n19. Concurrent treatment with quinolone antibiotics;\n20. Has a history of chronic alcoholism (determined by the investigator);\n21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months;\n22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}